Make it better together

06th November 2026

To
The Listing Department,
National Stock Exchange of India Limited
NSE Symbol: **SAILIFE**

To
The Corporate Relations Department,
BSE Limited
BSE Scrip code: **544306**

Dear Sir/Madam,

Ref: **Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").**

Sub: **Investor Presentation on the Un-audited Standalone and Consolidated Financial Results for the second quarter and half year ended 30th September 2026.**

Referring to our latter dated 19th October 2026 and pursuant to Regulation 30 of SEBI Listing Regulations we are enclosing herewith the Investor Presentation on Un-audited Standalone and Consolidated Financial Results for the second quarter and half year ended 30th September 2026. The presentation will be used during the Earnings Conference Call scheduled to be held on Friday, 06th November 2026 at 11:00 A.M. (IST).

Further, the above-mentioned presentation is also available on the Website of the Company on following path: https://sailife.com/#**> Investors> Financial Information> FY 2027> Earnings Presentation> Q2> Download (**https://sailife.com/financial-information/**)**.

Kindly take the above information on your record.

Thanking you.

Yours sincerely,
For **Sai Life Sciences Limited**

RUNA KARAN

Digitally signed by RUNA KARAN
Date: 2026.11.06 00:07:38 +05'30'

Runa Karan
Company Secretary & Compliance Officer
Membership No. A13721

Encl.: As Above

Sai Life Sciences Investor Presentation

November 05, 2026

Great Place To Work. Certified OCT 2026-OCT 2027 INDIA



Safe Harbour

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements", These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

All rights reserved © 2026 Sai Life Sciences Limited



Sai

“Q2 FY27 was a strong quarter for Sai, with continued business momentum and progress across our key strategic priorities. We see growing traction with global pharmaceutical companies, increasing adoption of our integrated outsourcing model, and continued progress in building the capacity and capabilities required to support customers over the long term. Importantly, we are seeing customer engagements evolve from individual projects into larger, more strategic relationships spanning discovery, development and manufacturing.”

Krishna Kanumuri
MD & CEO

All rights reserved © 2026 Sai Life Sciences Limited



"We are pleased to report a healthy performance this quarter, with revenue growing by 23% year-on-year. The performance was broad-based, with both CRO and CDMO delivering healthy growth, while EBITDA margins stood at 28%. We continue to expect a stronger second half, supported by the progression of our development and commercial pipeline and the ramp-up of new capacity. Our capacity and capability expansion programme remains on track with a total of ₹621 crore invested in H1 FY27."

Siva Chittor
Whole-time Director & CFO

All rights reserved © 2026 Sai Life Sciences Limited

Executive Summary



All rights reserved © 2026 Sai Life Sciences Limited

H1 FY27 Half-yearly Snapshot

₹ 1,213 Cr
Revenue
▲ 17% YoY

₹ 893 Cr
Material Margin
▲ 19% YoY

₹ 335 Cr
EBITDA
▲ 19% YoY

₹ 172 Cr
PAT
▲ 19% YoY

62 %
CDMO Revenue Mix

38 %
CRO Revenue Mix

₹ 621 Cr
Capex Incurred

All rights reserved © 2026 Sai Life Sciences Limited

Q2 FY27 Quarterly Snapshot

Sai

₹ 659 Cr
Revenue
▲ 23% YoY

₹ 484 Cr
Material Margin
▲ 22% YoY

₹ 187 Cr
EBITDA
▲ 20% YoY

₹ 98 Cr
PAT
▲ 17% YoY

64 %
CDMO Revenue Mix

36%
CRO Revenue Mix


₹ 358 Cr
Capex Incurred

67 %
Capacity Utilization

All rights reserved © 2026 Sai Life Sciences Limited


Consolidated Financial Highlights (Half Yearly)

Revenue (₹Cr)




17%
YoY Growth

Material Margin (₹Cr) & Margin (%)




19%
YoY Growth

EBITDA* (₹Cr) & Margin (%)



19%
YoY Growth

PAT (₹Cr) & Margin (%)




19%
YoY Growth

* including forex

All rights reserved © 2026 Sai Life Sciences Limited


Consolidated Financial Highlights (Quarterly)

Revenue (₹Cr)




23%
YoY Growth

Material Margin (₹Cr) & Margin (%)




22%
YoY Growth

EBITDA* (₹Cr) & Margin (%)



20%
YoY Growth

PAT (₹Cr) & Margin (%)



17%
YoY Growth

* including forex

All rights reserved © 2026 Sai Life Sciences Limited

Business Updates

Commenced operations with our first end-to-end integrated collaboration that we had onboarded last quarter; expected to be fully functional in Q3







All rights reserved © 2026 Sai Life Sciences Limited

Business Updates

- Commenced operations with our first end-to-end integrated collaboration that we had onboarded last quarter; expected to be fully functional in Q3
- Converted another large pharma relationship into a similar strategic engagement
- Working on expanding the integrated outsourcing model with other large pharma – discussions underway with few more companies
- Added one molecule to late phase pipeline; one molecule advanced from late phase to commercial
- Capex spend for 6M FY27 was Rs. 621 Crores (Q2 at Rs. 358 Crores); On track for the overall capex projection of Rs. 1,100 to 1,300 Crores
- Unit 2 and Unit 4 received Zero Waste to Landfill Platinum certification, with over 95% of waste diverted from landfills
- Certified Great Place To Work® for 2026–27





Company Overview

All rights reserved © 2026 Sai Life Sciences Limited

Sai Life Sciences: At a Glance



Integrated CRDMO Contract Research, Development and Manufacturing Organization

Outsourcing partner to pharma innovators

Offer complete services from drug discovery to manufacturing

27 Years of Expertise

Founded in 1999, **Sai Life Sciences has transformed into an integrated CRDMO,** delivering value across the pharma lifecycle from early discovery to commercial manufacturing

Global Partner of Choice

Trusted by 300+ global clients, including **19 of the top 25 global pharma companies** across the US, UK, EU, and Japan

Expansive Infrastructure

World-class R&D and manufacturing facilities across **Hyderabad, Bidar, Manchester, and Boston**

Innovation-Led Growth

Focused investments in **next- gen modalities** like Peptides, ADCs and Oligos; empowered by digital transformation, automation, and AI/ML to accelerate delivery and differentiation

All rights reserved © 2026 Sai Life Sciences Limited

Key Highlights

Fastest growing Indian CRDMO
over the last 5 years

NSE/BSE
Listed on the Indian Stock Exchanges in Dec 2024

4,400+
Total employees*

300+
Active customers across US, UK, EU, Japan

USFDA, PMDA
100% successful track record of regulatory inspections across our R&D and manufacturing facilities.

Diverse therapy areas
Oncology, CNS, Metabolic diseases, Inflammation, Antivirals, Rare diseases and more

11+ years
Enduring customer relationships

19/25
of the largest pharmaceutical companies are customers†

One-stop platform
for discovery, development and manufacturing

26% CAGR
Revenue growth over the last 5 years

34
Active NCE commercial molecules*

50+
Programs advanced to Candidate Selection/ IND or Phase I/II/III

14
Phase III/ pre-registration*

5
Molecules from discovery to market

*Note: Data as on 31 March 2026 | * Data as on 30 Sep 2026 | † In terms of market cap for CY 2025*

All rights reserved © 2026 Sai Life Sciences Limited

Growth journey

1999 – 2008

Founding & early biotech foray

- Incorporated in 1999; began as a medicinal chemistry partner to US biotech firms
- Expanded into Process R&D and small-scale manufacturing aligned with the needs of Biotechs clients

2009 – 2013

CDMO pivot

- First USFDA approval of Unit 4
- Expanded R&D (Unit 2) to enable large-scale pharma CDMO services
- Added 100 KL capacity at Unit 4
- Animal facility received AAALAC accreditation

2014 – 2018

Biology foray; CDMO Consolidation

- Cleared USFDA & PMDA audits at multiple sites
- Integrated Biology services; becoming end-to-end Discovery partner
- Added 120 KL (PB-07) and 170 KL (PB-08) blocks at Unit 4

2019 – 2023

Globalization, scaled-up integrated CRDMO

- Entered global markets: labs in Manchester & Boston
- Commissioned Clean Room, Amidites, and HPAPI blocks at Unit 4
- Strategic partnership with Schrödinger to enhance discovery science
- Continued regulatory track record and expansion of global footprint

2024 – Present

Increasing capacity & strengthening new-age modalities

- Listed on NSE & BSE
- Opened first building at Unit 8, being utilized for a large pharma collaboration
- Broke ground for a new Process R&D Block at Unit 2 Hyderabad, doubling PRD capacity, and adding capabilities in early phase peptide development and clinical formulations
- Building additional production capacity at Unit 4, Bidar and acquired land for new greenfield site in Choutuppal

All rights reserved © 2026 Sai Life Sciences Limited

Global Presence

Research laboratories for discovery and development located near overseas innovation hubs in Greater Boston, US and Manchester, UK, complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India.



Strategically located to combine innovation access, client proximity, and cost efficiency

Global Team

4,400+
Employees

2,500+
In R&D


700+
In Manufacturing

350+
In Quality

Note: Data as on 30 Sep 2026

All rights reserved © 2026 Sai Life Sciences Limited

Integrated CRDMO delivering value across the value chain



Seamless Integration

One-stop solution from research to commercial production

Regulatory Excellence


Compliant with global standards (US FDA, PMDA, COFEPRIS)

Scalable & Flexible

Supporting emerging biotech & leading pharma companies

All rights reserved © 2026 Sai Life Sciences Limited

Seamless integration across the NCE development value chain with focus on small molecules



Discovery

From target ID & validation to IND Stage through Creative Chemistry, Complex Biology, DMPK & Toxicology.

- Integrated Drug Discovery
- Complex Chemical Synthesis
- In vitro and in vivo pharmacology
- Comprehensive ADME and PK profiling
- Toxicology evaluation



Development

Complex chemical synthesis from development to commercialization.

- Advanced labs for early, late phase and commercial delivery
- Comprehensive analytical capabilities
- Fully equipped process safety lab
- Pilot plant and early phase delivery block
- HPAPI (< 0.1µg/m^3) capability
- Technology platforms – Bio catalysis, Flow chemistry, Chemo catalysis, Continuous extraction, Continuous distillation



Manufacturing


- 700 KL Capacity
- 80 Production trains
- 0.25 – 12 KL reactor sizes
- Containment level of 1 µg/m3
- 11 Clean Rooms of ISO – 8 (Class 100,000)
- Sensitive reactions block
- HPAPI (< 0.1µg/m^3) block w/ 8 reactors
- Lyophilization at pilot & commercial scale
- High pressure block
- Moisture sensitive block
- Column chromatography & cryogenic reaction

All rights reserved © 2026 Sai Life Sciences Limited


Discovery Services spanning the entire journey from Target Validation to IND

Integrated services: Synthetic & Medicinal Chemistry, CADD, Biology, DMPK and Toxicology

- Target Evaluation
- HIT ID




- Lead Candidate
- In vivo Pharmacology
- Toxicology
- Formulations




All rights reserved © 2026 Sai Life Sciences Limited

Discovery Services (CRO)

Consistent Revenue Growth (₹ Cr)



Customer Split %



* Discovery services (including chemistry, biology and/or DMPK services)

Client Stickiness

>65% Revenues from customers in FY23-26 who availed more than one Discovery services(*)

Automation

Focus on automation and scale in DMPK and biology, enabling us to handle large, integrated programs

Modalities Expansion

Expanding capabilities in ADCs, TPDs, Peptides, CGTs, Oligos, and more.

All rights reserved © 2026 Sai Life Sciences Limited

Discovery Services: Scaling Innovation, Driving Impact

>65% of Discovery programs are now integrated, with active use of next-gen biology, automation, and AI to accelerate development and improve outcomes

Expanded Core Capabilities



Scaled Chemistry, Biology, DMPK, and In Vivo labs delivering faster, parallelized research

Colocalized & Global Teams



Hyderabad campus and Boston Biology Lab enable seamless collaboration and rapid tech transfer

Tech-Enabled Drug Discovery



AI-enabled retrosynthesis tools
High-throughput Experimentation
DMPK automation
CADD in silico tools

Specialized Modalities



Peptides, ADC payloads, Oligos, TPDs and driving high-value Discovery growth

Next-Gen Preclinical Models




Organoids and spheroids enable predictive, FDA-aligned efficacy and toxicity testing

Technology advancements are transforming Sai's Discovery platform into a scalable, high-value growth engine

All rights reserved © 2026 Sai Life Sciences Limited

Development Services from H2L to Commercial Supply


Underpinned by integrated scientific approaches applied in a phase-appropriate manner




All rights reserved © 2026 Sai Life Sciences Limited

CMC Services (CDMO)

Consistent Revenue Growth (₹ Cr)




Customer Split %



- End-to-End capabilities from **IND through to commercialization**
- Focus on **Complex Chemistry,** ADC Payloads & Linkers
- **Modern, GMP-compliant facilities** across UK and India
- **Flexibility** to support both small-scale clinical supplies and large-scale commercial production
- Proven track record of **commercializing NCEs**
- **Robust regulatory record** with USFDA and PMDA
- **155 Programs** in the pipeline across multiple therapy areas
- **Clear Regulatory Record:** USFDA, PMDA
- At the forefront of **digitalization, automation and sustainability**

Business Mix Revenue Contribution – By Therapy (%) – FY26




Note: Therapy area contribution varies year-to-year based on client portfolio mix and project timelines. Not indicative of overall market trends

All rights reserved © 2026 Sai Life Sciences Limited

New Modalities: Fortifying foundation to build scale

New Modalities Revenue Contribution (%)



Peptides

Complement peptide discovery with process and scale-up facilities for clinical supplies; focus on commercial supply of fragments before evolving to full-scale peptide manufacturing.

Antibody-Drug Conjugates

Enhancing conjugation in Discovery; upgrading to class 6 containment for end-to-end support. Evaluating clinical conjugation and fill-finish for clinical supply

Oligonucleotides

Involved in multiple projects with Pharma from development to commercial; to focus only on making amidites.

Lipids

Involved in supplying lipids for last few years; looking to expand capacity

All rights reserved © 2026 Sai Life Sciences Limited

Our Strengths



All rights reserved © 2026 Sai Life Sciences Limited

IT-Driven Excellence: Digitization & Beyond

Digitization
2017 onwards

- Converting data, documents and processes from paper/ analog to digital
- **R&D and Mfg processes progressively digitized to current levels of 85% digitization**
- GMP Pro and ELN implementation
- QR Code & Label Management
- Learning Management System
- Audit Management System
- Laboratory Information Management System
- Validation Life Cycle Management System

Digitalization
2022 onwards

- Use of digitized data for effective monitoring through visual interactive dashboards.
- **Interactive Business Intelligence dashboards created using real-time data across functions and use cases.**
- Batch Quality, Yield, Experiments, Equipment Occupancy, Staffing status, QMS, etc.

Digital Transformation
2023 onwards

- Integration of digital technologies into all aspects of business operations
- **Leveraging large data sets with AIML models to create prediction models.**
- Digital Transformation Initiatives
- AI/ML - Manufacturing Process Prediction Model

Looking Ahead



Digitization process expected to be complete by 2027



Continued adoption of BI models to aid faster decision-making



AI/ML model proof-of-concept outcome to emerge in 2026.



Based on results, further integration into operations will be undertaken.

All rights reserved © 2026 Sai Life Sciences Limited

Global-Standard Operations, End-to-End

Quality Assurance

- 350+ QA/QC professionals across sites
- Integrated e-systems: LIMS, e-QMS
- QA independent; reports to CEO
- Audited by USFDA, EMA, PMDA, Indian regulators
- Focus on data integrity & global compliance

Sustainability Leadership

- 100% renewable energy at Bidar site
- Zero Liquid Discharge: water-neutral ops
- Carbon roadmap approved by SBTi
- Low-emission logistics via DHL

Safety & EHS Leadership

- Embedded Process Safety from quote to execution phase; rigorous lifecycle safety assessments.
- Plant Intermediates areas & lab fume cupboards validated down to 1µg/ m^3 containment
- First Indian company to join the PSCI membership; >30 PSCI Audits over the past 7 years
- Platinum rating by EcoVadis

All rights reserved © 2026 Sai Life Sciences Limited



Annexure

All rights reserved © 2026 Sai Life Sciences Limited

Consolidated Statement of Profit and Loss

Particulars (₹ Cr)	Q2FY27	Q1FY27	Q2FY26	H1FY27	H1FY26
Revenue from operations	659	554	537	1213	1034
Other income	3	4	5	7	11
Total income	**662**	**558**	**542**	**1220**	**1045**
Expenses					
Cost of materials consumed and changes in inventories	175	145	140	320	281
Employee benefits expense	198	180	163	378	323
Other expenses	99	80	89	181	162
Forex (gain)/loss	(1)	1	(10)	0	(14)
EBITDA	**187**	**148**	**156**	**335**	**281**
EBITDA Margin	*28%*	*27%*	*29%*	*28%*	*27%*
Finance costs	11	8	9	19	22
Depreciation and amortisation expense	48	46	40	94	77
Profit before tax	**131**	**98**	**112**	**229**	**193**
Tax expense	33	25	28	58	49
Profit after tax	**98**	**73**	**84**	**172**	**144**

All rights reserved © 2026 Sai Life Sciences Limited

Consolidated Balance Sheet

Assets (₹ Cr)	Sep 26	Mar 26
Non current assets		
Property, plant, and equipment	1,741	1,534
Right of use of assets	287	274
Capital work in progress	560	270
Intangible assets under development	12	-
Intangible assets	6	6
Financial assets		
- Investments	4	4
- Other financial assets	76	58
Deferred tax assets	12	13
Non current tax assets (net)	3	3
Other non-current assets	60	52
Total non-current assets	**2,762**	**2,216**
Current Assets		
Inventories	242	151
Financial assets		
- Investments	48	47
- Trade receivables	342	374
- Cash and bank balances	59	111
- Other financial assets	63	104
Other current assets	685	624
Total current assets	**1,441**	**1,411**
TOTAL ASSETS	**4,202**	**3,626**

Equity and Liabilities (₹ Cr)	Sep 26	Mar 26
Equity		
Equity share capital	21	21
Other equity	2,667	2,463
Total equity	**2,688**	**2,484**
Non current liabilities		
Financial liabilities		
- Borrowings	30	21
- Lease liabilities	115	128
Provisions	39	32
Deferred tax liabilities	146	128
Total non-current liabilities	**329**	**309**
Current liabilities		
Financial liabilities		
- Borrowings	418	75
- Lease liabilities	57	66
- Trade payables	273	285
- Other financial liabilities	180	164
Other current liabilities	161	173
Provisions	23	20
Current tax liabilities (net)	74	52
Total Current Liabilities	**1,185**	**834**
TOTAL EQUITY AND LIABILITIES	**4,202**	**3,626**

All rights reserved © 2026 Sai Life Sciences Limited

Awards, Certifications & Accreditations

Sai

Accelerating the Discovery, Development and Manufacturing of small molecules

ISO 14001:2015, ISO 45001:2018, ISO 50001:2018 & ISO 27001:2022 certifications

Certificate of Registration: Information Security Management System – ISO/IEC 27001:2013

Signatory of United Nations Global Compact (UNGC)

Eco Vadis Platinum Medal for Sustainability

Certified Great Place To Work

Member of:

PSCI Pharmaceutical Supply Chain Initiative – Building responsible supply chains

ACS Green Chemistry Institute Pharmaceutical Roundtable

Certified for Social Accountability and ethical workplace practices

GSK's Environmental Sustainability Supplier award 2021 in the 'Primary Manufacturing' category

Bayer Supplier Decarbonization Award 2025 finalist

All rights reserved © 2026 Sai Life Sciences Limited

Glossary

APIs	Active pharmaceutical ingredients
Biotechs	Biotechnology companies, often referred to as biotech companies, are largely startups in the pharmaceutical sector which typically focus on developing innovative drugs and drug development technologies to address unmet medical needs
Blockbuster End Molecules	Blockbusters are drug products with annual sales of over US$1 billion in the Financial Year 2023
CDSCO	Central Drug Standards Control Organization, India
CMC / CDMO	Chemistry, Manufacturing and Control / Contract Development and Manufacturing Organization
CMO	Contract Manufacturing Organization
COFEPRIS Mexico	Federal Commission for the Protection against Sanitary Risk of Mexico
CRDMO	Contract Research, Development, And Manufacturing Organization
CRO	Contract Research Organization
DMPK	Drug metabolism and pharmacokinetics
GATT	General Agreement on Tariffs and Trade
Generic drugs	Refer to pharmaceutical drugs that have the same chemical composition as the original innovator drug and can be sold by companies after the patent on the original drug expires
Innovation Clusters/Hubs	Nine regions identified by Frost and Sullivan including Boston/Cambridge in Massachusetts, Manchester/London/Cambridge in UK, Chicago in Illinois, New Jersey, New York, Paris in France, Switzerland and Japan. In 2022, approximately 57% of global R&D spending were in these nine pharma hubs
Innovator Drugs	Refer to first drugs created containing specific active ingredients and undergo approval or patent process for use
Large Molecule	Have a large molecular weight and made of proteins that are complex in structure compared to small molecule drugs. Costly to manufacture and, at this time, in most cases can only be administered by injection or infusion. Typically manufactured biologically, i.e. extracted from living organisms, but often include certain synthetic chemistry processes
Large Pharma Companies	Pharma companies with revenues > USD 10 billion
Mid Pharma Companies	Pharma companies with revenues in range of USD 500 million to USD 10 billion
NCE	New chemical entities
PMDA	Pharmaceuticals and Medical Devices Agency, Japan
Small Molecule	Organic compound with low molecular weight, small molecule drugs are known for their affordability, ease of administration (largely orally), and broad therapeutic coverage. Typically manufactured using synthetic chemistry processes
Small Pharma Companies	Pharma companies with revenues lower than USD 500 million
TRIPS	Trade-Related Aspects of Intellectual Property Rights
USFDA	United States Food and Drug Administration

All rights reserved © 2026 Sai Life Sciences Limited

Sai

Make it
better together

Thank You

For more details please contact:

Investorrelation@sailife.com

© Sai Life Sciences Limited.

L4, SLN Terminus, Gachibowli, Hyderabad 500032, Telangana, India.